CoMentis, Inc.

13 articles about CoMentis, Inc.

• CoMentis, Inc. And Anvyl Announce The Initiation Of Clinical Trials For APN1125 For The Treatment Of Schizophrenia

  1/9/2015

• Astellas Pharma Inc., CoMentis, Inc. Terminate Alzheimer's Agreement

  10/17/2014

• CoMentis, Inc. and Anvyl Announce Formation of Alpharmagen, a Joint Venture to Explore Nicotinic Modulators

  6/14/2013

• Terence A. Kelly, Ph.D., Joins CoMentis, Inc. as Senior Vice President for Discovery and Preclinical Development

  7/12/2010

• CoMentis, Inc. and Astellas Pharma Inc. to Present Alzheimer's Disease Research at International Conference on Alzheimer's Disease (ICAD)

  7/28/2008

• New Alzheimer's Treatment Completes First Phase Of Testing

  1/28/2008

• CoMentis, Inc. Announces Proof-of-Activity Data From Its Phase I Study of Disease-Modifying Alzheimer's Disease Therapy

  1/8/2008

• CoMentis, Inc. Announces Appointment of John L. Higgins to Board of Directors

  1/8/2008

• Juvenile Diabetes Research Foundation Partners With CoMentis, Inc. for Diabetic Macular Edema Clinical Trial

  9/20/2007

• Juvenile Diabetes Research Foundation Partners with CoMentis, Inc. for Diabetic Macular Edema Clinical Trial

  9/20/2007

• CoMentis, Inc. Receives FDA Clearance to Begin Human Clinical Trials for Its Disease-Modifying Alzheimer's Therapy

  6/18/2007

• CoMentis, Inc. Announces Appointment of Martin Tolar, M.D., Ph.D., as Vice President of Strategic and Corporate Development

  6/6/2007

• CoMentis, Inc. Initiates Phase II Clinical Trial for AMD Eye Drop Therapy

  4/10/2007